Omeros corporation announces late-breaking presentation of oms906 data at the 2023 european hematology association (eha) congress

Seattle--(business wire)--omeros corporation (nasdaq: omer) today announced that data from a pre-specified interim analysis of its ongoing phase 1b clinical trial of oms906, the company's lead masp-3 inhibitor, in complement-inhibitor-naÏve adults with paroxysmal nocturnal hemoglobinuria (pnh), a rare and life-threatening hemolytic blood disorder, will be shared at the 2023 european hematology association (eha) congress in frankfurt, germany. identified as one of the top five late-breaking subm.
OMER Ratings Summary
OMER Quant Ranking